June 17, 2025
MILAN — The treatment landscape for relapsed and refractory multiple myeloma (RRMM) has shifted dramatically with the emergence of immunotherapies such as chimeric antigen receptor (CAR) […]
June 17, 2025
Naval Daver, MD, who leads a number of acute myeloid leukemia (AML) research trials at MD Anderson Cancer Center in Houston, looks forward to a future […]
June 17, 2025
TOPLINE: A study at two US medical centers found that patients with brain metastases from gastrointestinal (GI) cancers had significantly worse overall survival and intracranial progression-free […]
June 17, 2025
TOPLINE: Analysis reveals initiating anal cancer screening at age 35 years or older among men who have sex with men (MSM) with HIV is cost-effective. A […]
June 16, 2025
TOPLINE: Asciminib, a first-in-class BCR–ABL1 TKI, showed high molecular response rates and was well tolerated in the first prospective trial of its kind evaluating the drug […]
June 16, 2025
MILAN — An unexpected highlight here at this year’s European Hematology Association (EHA) Congress came from beyond planet Earth. In a packed session titled Space Hematology, […]
June 16, 2025
TOPLINE: A novel, single-use on-body injector (OBI) for isatuximab in multiple myeloma is noninferior to the standard intravenous (IV) formulation in efficacy and pharmacokinetics and has […]
June 16, 2025
TOPLINE: Combination therapy with avelumab plus axitinib demonstrated a clinical benefit in patients with advanced gastrointestinal stromal tumour (GIST), achieving a 69.6% disease control rate and […]
June 16, 2025
TOPLINE: The programmed cell death protein 1 (PD-1) inhibitor drug sintilimab in combination with the standard chemotherapy regimen of ifosfamide, carboplatin, and etoposide (ICE) shows significant […]